<a href="https://laohu8.com/S/ELEV">Elevation Oncology</a> Inc. Announces Regulatory Changes Following Merger and Delisting from Nasdaq
Elevation Oncology Inc. recently announced a significant regulatory update following its merger with Concentra Biosciences, LLC. On July 23, 2025, the company completed a merger, resulting in its shares being delisted from the Nasdaq Stock Market. Elevation Oncology requested Nasdaq to suspend trading of its shares and filed a Notification of Removal from Listing with the SEC. Furthermore, the surviving corporation intends to terminate the registration of its shares and suspend reporting obligations under the Securities Exchange Act. This move marks a change in control, as Elevation Oncology is now a wholly owned subsidiary of Concentra. Additionally, all previous directors have resigned, with new directors and officers from Merger Sub assuming their roles.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elevation Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-026864), on July 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.